Equillium’s lupus drug improves kidney biomarker, teeing up opt-in decision from Ono

Equillium’s add-on lupus treatment improved a biomarker of kidney function in an unblinded phase 1 study, setting the ball rolling toward Ono Pharmaceuticals’ court for future development work.